Metraipolis › archive › dc_79312c8d1fbb

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results — Europe PMC PMID:42309525

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42309525
DOI
10.1093/ecco-jcc/jjag077
License (as archived)
solo-consultazione
Archived
2026-11-01T00:51:44.359Z
SHA-256 of the archived text
da97191c3a37ced6ad584d60ddb88bea28c38fcb48c2b73a4bb2a7a8c5d7325c
Stable URL of this page
https://metraipolis.com/documento/dc_79312c8d1fbb

How to cite

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results — Europe PMC PMID:42309525 — Europe PMC (en), https://europepmc.org/article/MED/42309525 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_79312c8d1fbb (Metraipolis archive dc_79312c8d1fbb, sha256 da97191c3a37ced6ad584d60ddb88bea28c38fcb48c2b73a4bb2a7a8c5d7325c)
BibTeX
@misc{dc79312c8d1fbb,
  title = {Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results — Europe PMC PMID:42309525},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42309525},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_79312c8d1fbb; sha256 da97191c3a37ced6ad584d60ddb88bea28c38fcb48c2b73a4bb2a7a8c5d7325c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42309525. Agents can read the archived copy with the MCP tool read_document.